Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner -See The Biology Behind: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001.
Pn. Munster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner -See The Biology Behind: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001., CLIN CANC R, 7(8), 2001, pp. 2228-2236
17-allyl-aminogeldanamycin (17-AAG) is an ansamycin antibiotic that binds t
o a highly conserved pocket in the Hsp90 chaperone protein and inhibits its
function. Hsp90 is required for the refolding of proteins during cellular
stress and the conformational maturation of certain signaling proteins. 17-
AAG has antitumor activity in cell culture and animal xenograft models and
is currently in clinical trial. It causes an RB-dependent G(1) arrest, diff
erentiation, and apoptosis. RB-negative cells arrest in mitosis and undergo
apoptosis. Hsp90 plays an important role in the cellular response to envir
onmental stress. Therefore, we tested whether the regulation of Hsp90 funct
ion by 17-AAG could sensitize cells to cytotoxic agents. 17-AAG sensitized
tumor cells to Taxol and doxorubicin. Taxanes cause growth arrest in mitosi
s and apoptosis. The addition of 17-AAG to cells after exposure to Taxol si
gnificantly increased both the activation of caspases 9 and 3 and apoptosis
. In cells with intact RB, exposure to 17-AAG before Taxol resulted in G(1)
arrest and abrogated apoptosis. Schedule dependence was not seen in cells
with mutated RB, because both agents blocked cells in mitosis. Schedule- or
RB-dependence was also not observed when cells were treated with 17-AAG an
d doxorubicin, a DNA-intercalating agent that acts on different phases of t
he cell cycle. These findings suggest that inhibition of Hsp90 function by
17-AAG enhances the administration and the RB status significantly influenc
e efficacy.